Form 4: GeneDx Director Jason Ryan Reports Routine Stock and RSU Transactions

GeneDx Holdings Corp. Director Jason Ryan has filed a Form 4 detailing the acquisition of new Restricted Stock Units and the conversion of existing RSUs into Class A Common Stock.

Summary

• Jason Ryan, a Director of GeneDx Holdings Corp. (WGS), reported transactions on June 18, 2025.
• He was granted 3,576 new Restricted Stock Units (RSUs) at a price of $0.
• He exercised 12,924 existing Restricted Stock Units (RSUs), converting them into 12,924 shares of Class A Common Stock at a price of $0.
• Following these transactions, Mr. Ryan directly beneficially owns 13,054 shares of Class A Common Stock and indirectly owns 141,356 shares through the Jason Ryan 2024 GRAT.
• He also directly holds 3,576 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The document is a factual report of routine insider stock transactions and does not convey positive or negative sentiment regarding the company's performance or outlook.

Positives

• The grant of 3,576 new Restricted Stock Units aligns the director's incentives with shareholder value.
• The exercise of 12,924 Restricted Stock Units into Class A Common Stock demonstrates the conversion of equity incentives into direct share ownership.

Future Outlook

The Restricted Stock Units granted on June 18, 2025, are set to vest on the earlier of the next annual meeting of the Issuer's shareholders following the grant date or the first anniversary of the grant date, contingent on the Reporting Person's continued service to the Issuer.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies, reflecting changes in beneficial ownership by directors or officers as part of their compensation or investment activities. It does not provide specific industry-wide insights beyond the standard reporting requirements.

Related Party Transactions

• Jason Ryan's indirect beneficial ownership of 141,356 shares of Class A Common Stock is held through the Jason Ryan 2024 GRAT, which is a personal trust.

Stakeholder Impact

• Shareholders: The transactions represent a routine change in a director's equity holdings, aligning their interests with long-term company performance through stock ownership and RSU grants.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The vesting of the newly granted 3,576 Restricted Stock Units will occur on the earlier of the next annual shareholder meeting or the first anniversary of the grant date, subject to continued service.

Key Dates

Keywords

GeneDx Holdings Corp, WGS, SEC Form 4, Insider Trading, Director Stock Transactions, Restricted Stock Units, RSU Conversion, Beneficial Ownership, Equity Compensation